Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature

Arslan C., Sari E., Aksoy S., Altundag K.

EXPERT OPINION ON THERAPEUTIC TARGETS, cilt.15, sa.1, ss.21-30, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 15 Sayı: 1
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1517/14656566.2011.537260
  • Dergi Adı: EXPERT OPINION ON THERAPEUTIC TARGETS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.21-30
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Importance of the field: Hormone and human epidermal growth factor receptor 2 (HER-2) receptors are two important pharmaceutical targets that affect the survival of patients with metastatic breast cancer. Discordance of hormone and HER-2 receptors were reported in a series of studies. Receptor status was reported to change in both directions, yet alteration occurs mostly in the loss of positivity for both receptors. We do not know both the exact mechanism of this process or the contribution rate of technical mistakes; a number of mechanisms might be responsible.